ASH 2023 | An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, highlights the recent advancements in cellular therapies. These include the FDA approval of exagamglogene autotemcel and lovotibeglogene autotemcel, the first gene editing therapies for sickle cell disease (SCD), and ongoing progress in bispecific antibodies and CAR T-cells for the treatment of multiple myeloma (MM). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Amgen, Actinuum, Celgene/BMS, Omeros, Johnson & Johnson, Miltenyi, Takeda
Board of Directors/Advisory Committee: Amgen, Actinuum, Celgene/BMS, Kite Pharma, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Spectrum Pharma, Takeda
